Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnnology and Biomolecular Research 2021 March;33(1) > Minerva Biotechnology and Biomolecular Research 2021 March;33(1):6-11

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Biotechnology and Biomolecular Research 2021 March;33(1):6-11

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum

Gian P. CAVIGLIA 1, Chiara ROSSO 1 , Angelo ARMANDI 1, Davide G. RIBALDONE 1, 2, Rinaldo PELLICANO 1, 2, Elisabetta BUGIANESI 1, 2

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Division of Gastroenterology, Department of General and Specialist Medicine, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy


PDF


BACKGROUND: Connecting peptide (C-peptide) is the cleavage product of proinsulin and is released in blood in equimolar amounts to insulin. Compared to the latter, C-peptide has a longer plasma half-life and is less affected by hemolysis, therefore could be a useful marker of insulin production. We aimed to compare the analytical performance of two different chemiluminescent enzyme immunoassays (CLEIA) for the measurement of C-peptide in serum.
METHODS: Overall, 106 subjects (median age: 51 [20-75]; M/F: 72/34) with available serum samples were included in the study; 14 (13.2%) had a diagnosis of impaired fasting glucose (IFG) and 28 (26.4%) of type 2 diabetes mellitus (T2DM). C-peptide was measured in serum by Elecsys® C-peptide (Roche, Mannheim, Germany) and by Lumipulse® c-Peptide (Fujirebio, Tokyo, Japan) CLEIAs.
RESULTS: Median C-peptide levels measured by Elecsys® and Lumipulse® were comparable in our study cohort (2.6 [0.3-13.3] ng/mL vs. 2.54 (0.01-10.50) ng/mL, respectively; P=0.665). No random differences were observed between the two methods; the analytical agreement between both was satisfactory. C-peptide serum values were strongly correlated to insulin concentration (rs=0.626, P<0.001, for Elecsys®; rs=0.719, P<0.001, for Lumipulse®) and increased in a stepwise manner from patients with normal glucose tolerance to those with IFG and T2DM (P<0.001). Both CLEIAs showed an area under the curve >0.7 for the discrimination between patients with and without overt T2DM.
CONCLUSIONS: The Elecsys® and Lumipulse® C-peptide CLEIAs showed an adequate analytical agreement. The measurement of serum C-peptide may represent a valid surrogate of pancreatic β-cell function with a potential useful application in the clinical setting.


KEY WORDS: C-peptide; Glucose; Diabetes mellitus, type 2

top of page